PapersPMID:31987257
The effects of carnitine supplementation on clinical characteristics of patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials.
- findings
- 4
- compound
- 1
- endpoints
- 4
(R)-carnitine- Study, every finding
- meta-analysis
- Population, every finding
- Patients with non-alcoholic fatty liver disease; meta-analysis of 5 randomized placebo-controlled trials (334 individuals)
What moved
How to read these marks →“The results demonstrated that carnitine supplementation significantly reduced homeostasis model assessment of insulin resistance (HOMA-IR) (WMD: -0.91; 95 % CI: -1.11, -0.72; p < 0.001, I2 = 0.0 %) and the levels of aspartate aminotransferase (AST) (WMD: -16.62; 95 % CI: -28.11, -5.14; IU/l; p = 0.005, I2 = 93.5 %), alanine aminotransferase (ALT) (WMD: -33.39; 95 % CI: -45.13, -21.66; IU/l; p < 0.001, I2 = 93.4 %), and triglycerides (TG) (WMD: -22.13; 95 % CI: -38.91, -5.34; mg/dl; p = 0.01; I2 = 0.0 %).”
- Decreases HOMA-IR
very limited
- Effect
- −0.91 mean difference, 95% CI −1.11 to −0.72
- Decreases aspartate aminotransferase
very limitedreplicated ×2
- Effect
- −16.62 mean difference, 95% CI −28.11 to −5.14
- Decreases alanine aminotransferase
very limitedreplicated ×3
- Effect
- −33.39 mean difference, 95% CI −45.13 to −21.66
- Decreases triglycerides
very limited
- Effect
- −22.13 mean difference, 95% CI −38.91 to −5.34
Study record
- Design
- meta-analysis
- Species
- human
- Population
- patients with nonalcoholic fatty liver disease
- Participants
- 334
- Comparator
- placebo
- Duration
- not reported
- Endpoints measured
- 10